Efficacy and safety of Tongfu powder in acute pancreatitis patients with gastrointestinal dysfunction: a clinical trial

Miao, Benchun; Li, Fengwu; Zhang, Shuwen; Wang, Hong; Qi, Wenjie; Wang, Chao

doi:10.2147/dddt.s163645

Cited by 6 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have demonstrated that ROS formation is closely linked to AP (Kim, 2008;Thareja, Bhardwaj, Sateesh, & Saraya, 2009). This decrease also determines the se- (Li, Zhang, Zhou, Zhang, & Li, 2017;Miao et al, 2018). This decrease also determines the se- (Li, Zhang, Zhou, Zhang, & Li, 2017;Miao et al, 2018).…”

Section: Discussionmentioning

confidence: 93%

“…Recently, the published guidelines for AP treatment in China stated that Traditional Chinese Medicine (TCM), which involves the use of single plants or formulas, can be used as a promising complementary therapy for AP. It has also been demonstrated by experimental and clinical studies that plants and formulations used in TCM are effective in the treatment of AP (Li, Zhang, Zhou, Zhang, & Li, 2017;Miao et al, 2018). In this study, the beneficial effects of MC on AP have been explored.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

Myrtus communisleaf extract protects against cerulein‐induced acute pancreatitis in rats

et al. 2019

View full text Add to dashboard Cite

In this study, the aim was to examine the potential protective effects of Myrtus communis subsp. communis leaf ethanol extract (MC) treatment against acute pancreatitis (AP) in rats. Thirty‐two rats were grouped as the saline‐pretreated control (C), MC‐pretreated control (MC), saline‐pretreated AP (AP), and MC‐pretreated AP (MC + AP) groups. To induce AP, cerulein was administered (50 µg/kg) two times. The rats were given MC for 14 days before cerulein injection. Six hours after the final cerulein injection, the rats were sacrificed. Pancreatic damage was associated with an increase in the serum activity of lipase and amylase, the pancreatic activity of myeloperoxidase, and the pancreatic level of malondialdehyde, interleukin‐1β, and interleukin‐6. AP also led to a decrease in the pancreatic level of anti‐inflammatory interleukin‐10 and glutathione. Pretreatment with MC before the induction of AP significantly reduced the pancreatic damage observed during the histological examination as well as reversed the biochemical changes evoked by AP. Practical applications Acute pancreatitis is characterized by high mortality (average about 5%; severe cases may reach about 30%). The current treatment for acute pancreatitis is mainly symptomatic. The introduction of herbal drugs may lead to the development of a new strategy in the treatment of this disease. This study revealed that MC reduced pancreatic injury by decreasing pro‐inflammatory cytokines, increasing antioxidant capacity and anti‐inflammatory cytokine, IL‐10. To the authors’ knowledge, this research is the first report showing that MC inhibits the development of AP. This observation suggests that MC may be useful in the prevention and the treatment of AP in clinical settings.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 96%

Myrtus communisleaf extract protects against cerulein‐induced acute pancreatitis in rats

et al. 2019

View full text Add to dashboard Cite

show abstract

“…We included 102 studies with a total of 8830 patients (Figure 1). Eighty‐six studies (84%) were clinical trials 13–98 and 16 (14%) were observational studies 99–114 . Nine studies (7%) were only available in the form of a conference abstract; seven clinical trials and two observational studies 88–93,96,100,107 .…”

Section: Resultsmentioning

confidence: 99%

“…Twenty‐eight studies (65%) 38,53,59,61,68,72–75,78–82,87–91,93,97,98,106,107,109,110,112,114 reported patient‐centred outcomes including hospital LOS, mortality, surgical complications, infections, need for surgery and readmission rate.…”

Section: Resultsmentioning

confidence: 99%

Use of prokinetic agents in hospitalised adult patients: A scoping review

Crone

Møller

Bækgaard

et al. 2023

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

Background: Gastrointestinal motility is important for adequate uptake of fluids and nutrition but is often impaired in hospitalised patients. Prokinetic agents enhance gastrointestinal motility and are prescribed for many hospitalised patients. In this scoping review, we aimed to systematically describe the body of evidence on the use of prokinetic agents in hospitalised patients. We hypothesised, that the body of evidence would be limited and derive from heterogeneous populations. Methods: We conducted this scoping review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews statement. We searched Medline, Embase, Epistemonikos and the Cochrane Library for studies assessing the use of prokinetic agents on any indication and outcome in adult hospitalised patients. We used a modified version of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of evidence. Results:We included 102 studies with a total of 8830 patients. Eighty-six studies were clinical trials (84%), and 52 (60%) of these were conducted in the intensive care unit, with feeding intolerance as the main indication. In the non-intensive care setting the indications were wider; most studies assessed use of prokinetic agents before gastroscopy to improve visualisation. The most studied prokinetic agent was metoclopramide (49% of studies) followed by erythromycin (31%). In total 147 outcomes were assessed with only 67% of the included studies assessing patient-centred outcomes, and with gastric emptying as the most frequently reported outcome. Overall, the data provided no firm evidence on the balance between the desirable and undesirable effects of prokinetic agents. Conclusions:In this scoping review, we found that the studies addressing prokinetic agents in hospitalised adults had considerable variations in indications, drugs and outcomes assessed, and that the certainty of evidence was judged to be low to very low.

show abstract

“…Several prokinetic GI hormones, such as circulatory motilin and ghrelin, were reported to be decreased in AP 1,44,45 . Miao et al 46 treated AP patients with a special kind of traditional Chinese Medicine named Tongfu powder via umbilical compress therapy and reported improvement in GI dysmotility concurrent with an increase in motilin. However, motilin was not altered with the TEA treatment in the present study.…”

Section: Discussionmentioning

confidence: 99%

Integrative effects of transcutaneous electrical acustimulation on abdominal pain, gastrointestinal motility, and inflammation in patients with early‐stage acute pancreatitis

Xuan

Zhu

et al. 2021

Neurogastroenterology Motil

View full text Add to dashboard Cite

Background/Aims Gastrointestinal (GI) dysmotility in acute pancreatitis (AP) aggravates inflammation and results in severe complications. This study aimed to explore effects and possible mechanisms of transcutaneous electrical acustimulation (TEA) on abdominal pain, GI dysmotility, and inflammation in AP patients. Methods Forty‐two AP patients were blindly randomized to receive TEA (n = 21) at acupoints PC6 and ST36 or Sham‐TEA (n = 21) at sham points for 2 days. Symptom scores, gastric slow waves, autonomic functions (assessed by spectral analysis of heart rate variability), circulatory levels of motilin, ghrelin, and TNF‐α were measured before and after the treatment. Sixteen healthy controls (HCs) were also included without treatment for the assessment of gastric slow waves and biochemistry. Key Results Compared with Sham‐TEA, TEA decreased abdominal pain score (2.57 ± 1.78 vs. 1.33 ± 1.02, p < 0.05), bloating score (5.19 ± 1.21 vs. 0.76 ± 0.99, p < 0.001), the first defecation time (65.79 ± 19.51 h vs. 51.38 ± 17.19 h, p < 0.05); TEA, but not Sham‐TEA, improved the percentage of normal gastric slow waves by 41.6% (p < 0.05), reduced AP severity score (5.52 ± 2.04 vs. 3.90 ± 1.90, p < 0.05) and serum TNF‐α (7.59 ± 4.80 pg/ml vs. 4.68 ± 1.85 pg/ml, p < 0.05), and upregulated plasma ghrelin (0.85 ± 0.96 ng/ml vs. 2.00 ± 1.71 ng/ml, p = 0.001) but not motilin (33.08 ± 22.65 pg/ml vs. 24.12 ± 13.95 pg/ml, p > 0.05); TEA decreased sympathetic activity by 15.0% and increased vagal activity by 18.3% (both p < 0.05). Conclusions & Inferences TEA at PC6 and ST36 administrated at early stage of AP reduces abdominal pain, improves GI motility, and inhibits inflammatory cytokine, TNF‐α, probably mediated via the autonomic and ghrelin mechanisms.

show abstract

Efficacy and safety of Tongfu powder in acute pancreatitis patients with gastrointestinal dysfunction: a clinical trial

Cited by 6 publications

References 20 publications

Myrtus communisleaf extract protects against cerulein‐induced acute pancreatitis in rats

Myrtus communisleaf extract protects against cerulein‐induced acute pancreatitis in rats

Use of prokinetic agents in hospitalised adult patients: A scoping review

Integrative effects of transcutaneous electrical acustimulation on abdominal pain, gastrointestinal motility, and inflammation in patients with early‐stage acute pancreatitis

Contact Info

Product

Resources

About